AbbVie’s rheumatoid arthritis drug is performing well in trials.
U.S. drugmaker AbbVie said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to standard treatments.
Two doses of the drug, upadacitinib, induced a statistically significant reduction in symptoms compared to a placebo in the 12-week long study, AbbVie said.
Nearly half of the patients achieved low disease activity at both doses and around 30 percent achieved clinical remission, data showed.
Rheumatoid arthritis is a chronic inflammatory autoimmune disease in which the immune system attacks the tissues of the joints, causing inflammation, pain, joint damage and disability.
Upadacitinib is a once-daily pill belonging to a class of drugs known as Jak inhibitors, which block inflammation-causing enzymes known as Janus kinases.
Read full article: AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial
|Read Full Article: AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial|